Finally, a phase 2 trial is evaluating INCMGA00012 (a humanised mAb antagonistic to PD-1) in patients with unresectable or metastatic adenosquamous pancreatic cancer, a rare and more aggressive pancreatic cancer subtype, with worse survival outcomes than pancreatic adenocarcinoma (NCT04116073) [115]. Here, PDCD1 is linked to pancreatic neoplasm.